Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible isolates of the following Gram positive and Gram negative microorganisms- Staphylococcus aureus (including methicillin-susceptible and resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae ... Read more Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible isolates of the following Gram positive and Gram negative microorganisms- Staphylococcus aureus (including methicillin-susceptible and resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. Community-Acquired Bacterial Pneumonia (CABP) caused by susceptible isolates of the following Gram positive and Gram negative microorganisms- Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca and Escherichia coli.
Ceftaroline is a cephalosporin with activity against Gram-positive and Gram-negative bacteria. In vitro studies have shown that ceftaroline is bactericidal, due to inhibition of bacterial cell wall synthesis by binding to penicillin binding proteins (PBPs). Ceftaroline is also active against methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-nonsusceptible Streptococcus pneumoniae (PNSP) due to its affinity for the altered PBPs found in these organisms.
The duration of therapy should be guided by the severity and site of infection and the patient’s clinical and bacteriological progress. Indications Age Range Dosage Infusion Time Duration Acute Bacterial Skin and Skin Structure Infections 18 years and older 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (>33 kg) 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (≤33kg) 12 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days 2 months to <2 years 8 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days 0 to <2 months 6 mg/kg every 8 hours 30 to 60 minutes 5 to 14 days Community Acquired Bacterial Pneumonia 18 years and older 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (>33 kg) 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (≤33kg) 12 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days 2 months to <2 years 8 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
The common side effects include diarrhea, nausea, vomiting, abdominal pain, headache, dizziness, rash, pruritus, increased transaminases, phlebitis, pyrexia and infusion site reactions (erythema, phlebitis, pain). The uncommon side effects are anemia, leucopenia, thrombocytopenia, hypersensitivity/anaphylaxis, urticaria, Clostridium difficile colitis, prolonged prothrombin time, increased blood creatinine; and rarely eosinophilia.
Hypersensitivity to the active substance or to any of its excipients. Hypersensitivity to the cephalosporin class of antibacterials. Immediate and severe hypersensitivity (e.g., anaphylactic reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or carbapenems).
No clinical drug-drug interaction studies have been conducted with Cefamil-5. There is minimal potential for drug-drug interactions between Cefamil-5 and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow.
Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs, including Cefamil-5. If a hypersensitivity reaction occurs, discontinue Cefamil-5. Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including Cefamil-5. Evaluate if diarrhea occurs. Neurological adverse reactions have been reported in patients treated with cephalosporins, including Cefamil-5. If neurological adverse reactions occur, consider discontinuing Cefamil-5 or making appropriate dosage adjustments in patients with renal impairment. If anemia develops during or after therapy, a diagnostic workup for drug-induced hemolytic anemia should be performed and consideration given to discontinuation of Cefamil-5.